Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q86X52

UPID:
CHSS1_HUMAN

ALTERNATIVE NAMES:
Chondroitin glucuronyltransferase 1; Chondroitin synthase 1; Glucuronosyl-N-acetylgalactosaminyl-proteoglycan 4-beta-N-acetylgalactosaminyltransferase 1; N-acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase 1; N-acetylgalactosaminyltransferase 1

ALTERNATIVE UPACC:
Q86X52; Q6UX38; Q7LFU5; Q9Y2J5

BACKGROUND:
Chondroitin sulfate synthase 1, with alternative names such as Chondroitin synthase 1, plays a significant role in the synthesis of chondroitin sulfate, a key component of the extracellular matrix. This enzyme is responsible for transferring glucuronic acid and N-acetylgalactosamine to the growing chondroitin polymer, crucial for proper tissue development and maintenance.

THERAPEUTIC SIGNIFICANCE:
Given its critical function in the development of the extracellular matrix and its association with Temtamy preaxial brachydactyly syndrome, Chondroitin sulfate synthase 1 presents a promising target for therapeutic intervention. Exploring its role in disease mechanisms and tissue development could open doors to potential therapeutic strategies for a range of skeletal and connective tissue disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.